image
Healthcare - Biotechnology - NASDAQ - IE
$ 28.19
-0.564 %
$ 4.56 B
Market Cap
12.7
P/E
1. INTRINSIC VALUE

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.[ Read More ]

The intrinsic value of one ALKS stock under the base case scenario is HIDDEN Compared to the current market price of 28.2 USD, Alkermes plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALKS

image
FINANCIALS
1.66 B REVENUE
49.61%
414 M OPERATING INCOME
391.09%
356 M NET INCOME
324.78%
401 M OPERATING CASH FLOW
1807.21%
53.4 M INVESTING CASH FLOW
182.67%
-290 M FINANCING CASH FLOW
-18306.23%
378 M REVENUE
-5.26%
105 M OPERATING INCOME
-4.67%
92.4 M NET INCOME
-2.41%
81.6 M OPERATING CASH FLOW
-44.13%
-109 M INVESTING CASH FLOW
-210.86%
-111 M FINANCING CASH FLOW
-33.10%
Balance Sheet Decomposition Alkermes plc
image
Current Assets 1.49 B
Cash & Short-Term Investments 773 M
Receivables 333 M
Other Current Assets 379 M
Non-Current Assets 651 M
Long-Term Investments 39.9 M
PP&E 318 M
Other Non-Current Assets 292 M
Current Liabilities 520 M
Accounts Payable 65.6 M
Short-Term Debt 8.75 M
Other Current Liabilities 446 M
Non-Current Liabilities 413 M
Long-Term Debt 363 M
Other Non-Current Liabilities 49.9 M
EFFICIENCY
Earnings Waterfall Alkermes plc
image
Revenue 1.66 B
Cost Of Revenue 289 M
Gross Profit 1.37 B
Operating Expenses 996 M
Operating Income 414 M
Other Expenses 58.4 M
Net Income 356 M
RATIOS
82.64% GROSS MARGIN
82.64%
24.90% OPERATING MARGIN
24.90%
21.39% NET MARGIN
21.39%
29.58% ROE
29.58%
16.65% ROA
16.65%
34.15% ROIC
34.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alkermes plc
image
Net Income 356 M
Depreciation & Amortization 74.9 M
Capital Expenditures -48 M
Stock-Based Compensation 101 M
Change in Working Capital -36.7 M
Others -6.12 M
Free Cash Flow 353 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alkermes plc
image
Wall Street analysts predict an average 1-year price target for ALKS of $35.6 , with forecasts ranging from a low of $25 to a high of $50 .
ALKS Lowest Price Target Wall Street Target
25 USD -11.32%
ALKS Average Price Target Wall Street Target
35.6 USD 26.37%
ALKS Highest Price Target Wall Street Target
50 USD 77.37%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Alkermes plc
image
Sold
0-3 MONTHS
2.08 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
454 K USD 3
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 days ago
Nov 11, 2024
Sell 1.77 M USD
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
- 58996
30.0796 USD
1 week ago
Nov 06, 2024
Sell 309 K USD
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
- 10471
29.5262 USD
8 months ago
Mar 18, 2024
Sell 293 K USD
Nichols Christian Todd
SVP, Chief Commercial Officer
- 10417
28.1021 USD
8 months ago
Feb 27, 2024
Sell 75.9 K USD
Parisi Samuel Joseph
VP, Finance (Interim PAO)
- 2559
29.65 USD
9 months ago
Feb 15, 2024
Sell 85.7 K USD
LAURENCIN CATO T
Director
- 2690
31.85 USD
1 year ago
Jun 08, 2023
Sell 84 K USD
LAURENCIN CATO T
Director
- 2638
31.85 USD
1 year ago
Jun 07, 2023
Sell 88.2 K USD
LAURENCIN CATO T
Director
- 2800
31.5 USD
1 year ago
May 30, 2023
Sell 785 K USD
Nichols Christian Todd
SVP, Chief Commercial Officer
- 27134
28.9254 USD
1 year ago
May 09, 2023
Sell 1.29 M USD
Wysenski Nancy
Director
- 41250
31.2433 USD
2 years ago
Nov 14, 2022
Bought 816 K USD
Daglio David Angelo Jr.
Director
+ 35000
23.3067 USD
2 years ago
Jun 21, 2022
Sell 211 K USD
Nichols Christian Todd
SVP, Chief Commercial Officer
- 7474
28.2584 USD
7. News
Alkermes to Participate in Two Upcoming Investor Conferences DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. prnewswire.com - 5 days ago
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences – 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc  (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the 2024 Neuroscience Education Institute (NEI) Congress, taking place Nov. 7-10, 2024 in Colorado Springs, Colorado—represent important opportunities for Alkermes to showcase the breadth and depth of its work in neuroscience. prnewswire.com - 1 week ago
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. zacks.com - 3 weeks ago
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fye - JPMorgan Jason Gerberry - Bank of America Marc Goodman - Leerink Partners Ash Fermot - UBS Douglas Tsao - H.C. seekingalpha.com - 3 weeks ago
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 3 weeks ago
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. zacks.com - 3 weeks ago
Alkermes plc Reports Third Quarter 2024 Financial Results — Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year. prnewswire.com - 3 weeks ago
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. zacks.com - 3 weeks ago
Alkermes to Report Third Quarter Financial Results on October 24, 2024 DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. prnewswire.com - 1 month ago
Here's Why Alkermes (ALKS) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 1 month ago
Here's Why Alkermes (ALKS) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy DUBLIN , Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. prnewswire.com - 1 month ago
8. Profile Summary

Alkermes plc ALKS

image
COUNTRY IE
INDUSTRY Biotechnology
MARKET CAP $ 4.56 B
Dividend Yield 0.00%
Description Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Contact Connaught House, Dublin, 4 https://www.alkermes.com
IPO Date July 16, 1991
Employees 2100
Officers Mr. Peter Norman Senior Vice President of Policy & Government Relations Mr. Iain Michael Brown Senior Vice President & Chief Financial Officer Mr. Stephen Schiavo Senior Vice President & Chief Human Resources Officer Ms. Sandra Coombs Senior Vice President of Corporate Affairs & Investor Relations Mr. Samuel J. Parisi Interim Principal Accounting Officer & Vice President of Finance Mr. Richard F. Pops Chairman & Chief Executive Officer Mr. Blair C. Jackson Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer Dr. Craig C. Hopkinson M.D. Executive Vice President of Research & Development and Chief Medical Officer Dr. Floyd E. Bloom M.D. Founder Mr. Thomas Harvey Chief Information Officer & Senior Vice President of IT